JP2020514360A - Ｍｋ２阻害剤の形態および組成物 - Google Patents

Ｍｋ２阻害剤の形態および組成物 Download PDF

Info

Publication number
JP2020514360A
JP2020514360A JP2019550652A JP2019550652A JP2020514360A JP 2020514360 A JP2020514360 A JP 2020514360A JP 2019550652 A JP2019550652 A JP 2019550652A JP 2019550652 A JP2019550652 A JP 2019550652A JP 2020514360 A JP2020514360 A JP 2020514360A
Authority
JP
Japan
Prior art keywords
compound
acid
complex
peaks
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514360A5 (enExample
Inventor
ジャンシン・ハン
リアンフェン・ホアン
ウダイ・ジャイン
イン・リィ
ジョン・マロナ
ケビン・モルター
チッタリ・パッバ
アレクサンダー・エル・ルチェルマン
ジーン・シュー
ダオジョン・ゾウ
Original Assignee
セルジーン シーエーアール エルエルシー
セルジーン シーエーアール エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン シーエーアール エルエルシー, セルジーン シーエーアール エルエルシー filed Critical セルジーン シーエーアール エルエルシー
Publication of JP2020514360A publication Critical patent/JP2020514360A/ja
Publication of JP2020514360A5 publication Critical patent/JP2020514360A5/ja
Priority to JP2022172305A priority Critical patent/JP2023017840A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
JP2019550652A 2017-03-16 2018-03-15 Ｍｋ２阻害剤の形態および組成物 Pending JP2020514360A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022172305A JP2023017840A (ja) 2017-03-16 2022-10-27 Ｍｋ２阻害剤の形態および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
US62/472,015 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022172305A Division JP2023017840A (ja) 2017-03-16 2022-10-27 Ｍｋ２阻害剤の形態および組成物

Publications (2)

Publication Number Publication Date
JP2020514360A true JP2020514360A (ja) 2020-05-21
JP2020514360A5 JP2020514360A5 (enExample) 2021-04-22

Family

ID=63522534

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550652A Pending JP2020514360A (ja) 2017-03-16 2018-03-15 Ｍｋ２阻害剤の形態および組成物
JP2022172305A Pending JP2023017840A (ja) 2017-03-16 2022-10-27 Ｍｋ２阻害剤の形態および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022172305A Pending JP2023017840A (ja) 2017-03-16 2022-10-27 Ｍｋ２阻害剤の形態および組成物

Country Status (8)

Country Link
US (2) US10882867B2 (enExample)
EP (1) EP3595658A4 (enExample)
JP (2) JP2020514360A (enExample)
CN (1) CN110678178B (enExample)
AU (1) AU2018236286B2 (enExample)
CA (1) CA3054823A1 (enExample)
MX (1) MX393600B (enExample)
WO (1) WO2018170199A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512315A (ja) * 2017-03-16 2020-04-23 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201902326XA (en) 2014-09-17 2019-04-29 Celgene Car Llc Mk2 inhibitors and uses thereof
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
US9126978B2 (en) * 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
SG194216A1 (en) * 2011-04-21 2013-11-29 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
KR20150133172A (ko) * 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014210319A2 (en) * 2013-06-26 2014-12-31 The Trustees Of Columbia University In The City Of New York Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds
MX2017008994A (es) 2015-01-08 2018-09-18 Moerae Matrix Inc Formulacion de peptidos inhibidores mk2.
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
JP2020514361A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004812248 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004812249 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512315A (ja) * 2017-03-16 2020-04-23 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物

Also Published As

Publication number Publication date
US11629153B2 (en) 2023-04-18
EP3595658A4 (en) 2020-11-25
JP2023017840A (ja) 2023-02-07
US20200148701A1 (en) 2020-05-14
EP3595658A1 (en) 2020-01-22
US10882867B2 (en) 2021-01-05
WO2018170199A1 (en) 2018-09-20
US20210198276A1 (en) 2021-07-01
AU2018236286B2 (en) 2022-02-17
AU2018236286A1 (en) 2019-09-19
MX393600B (es) 2025-03-24
CN110678178A (zh) 2020-01-10
CA3054823A1 (en) 2018-09-20
MX2019010643A (es) 2019-10-17
CN110678178B (zh) 2023-10-03

Similar Documents

Publication Publication Date Title
US11629153B2 (en) Forms and compositions of a MK2 inhibitor
EA038195B1 (ru) Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
CN111601791B (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2016201280A1 (en) Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
TWI870440B (zh) 活化素受體樣激酶抑制劑之鹽及晶體形式
TWI771280B (zh) 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
TW202337447A (zh) 含氮并環類衍生物抑制劑的酸式鹽或晶型及其製備方法和應用
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
KR102891811B1 (ko) 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
US10544137B2 (en) PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
CA3041854A1 (en) Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
KR20160143842A (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물의 염 및 다형체
WO2025011618A9 (zh) 噻唑并吡嗪类化合物的盐或其结晶及其应用
WO2019057121A1 (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
TW202019908A (zh) 氮雜雙環基取代的三唑類衍生物的可藥用鹽、晶型及製備方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220628